#aahth ,,congress #b;d ,session ,h4 ,r4 #hccc ,,an ,,act ,to prohibit contracting with certain biotechnology providers1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,biosecure ,act4 #b4 ,prohibition on contracting with certain biotechnology providers 7a7 ,in general ,the head of an executive agency may not-- 7#a7 procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern2 or 7#b7 enter into a contract or extend or renew a contract with any entity that-- 7,a7 uses biotechnology equipment or services produced or provided by a biotechnology company of concern and acquired after the applicable effective date in subsection 7c7 in performance of the contract with the executive agency2 or 7,b7 enters into any contract the performance of which such entity knows or has reason to believe will require1 in performance of the contract with the executive agency1 the use of biotechnology equipment or services produced or provided by a biotechnology company of concern and acquired after the applicable effective date in subsection 7c74 7b7 ,prohibition on loan and grant funds ,the head of an executive agency may not obligate or expend loan or grant funds to1 and a loan or grant recipient may not use loan or grant funds to-- 7#a7 procure1 obtain1 or use any biotechnology equipment or services produced or provided by a biotechnology company of concern2 or 7#b7 enter into a contract or extend or renew a contract with an entity described in subsection 7a77#b74 7c7 ,effective dates 7#a7 ,certain entities ,with respect to the biotechnology companies of concern covered by subsection 7f77#b77;,a71 the prohibitions under subsections 7a7 and 7b7 shall take effect #fj days after the issuance of the regulation in subsection 7h74 7#b7 ,other entities ,with respect to the biotechnology companies of concern covered by subsection 7f77#b77;,b71 the prohibitions under subsections 7a7 and 7b7 shall take effect #ahj days after the issuance of the regulation in subsection 7h74 7#c7 ,rules of construction 7,a7 ,certain entities ,prior to ,january #a1 #bjcb1 with respect to biotechnology companies of concern covered by subsections 7f77#b77;,a71 subsections 7a77#b7 and 7b77#b7 shall not apply to biotechnology equipment or services produced or provided under a contract or agreement1 including previously negotiated contract options1 entered into before the effective date under paragraph 7#a74 7,b7 ,other entities ,prior to the date that is five years after the issuance of the regulation in subsection 7h7 that identifies a biotechnology company of concern covered by subsections 7f77#b77;,b71 subsections 7a77#b7 and 7b77#b7 shall not apply to biotechnology equipment or services produced or provided under a contract or agreement1 including previously negotiated contract options1 entered into before the effective date under paragraph 7#b74 7,c7 ,safe harbor ,the term biotechnology equipment or services produced or provided by a biotechnology company of concern shall not be construed to refer to any biotechnology equipment or services that were formerly1 but are no longer1 produced or provided by biotechnology companies of concern4 7d7 ,waiver authorities 7#a7 ,specific biotechnology exception 7,a7 ,waiver ,the head of the applicable executive agency may waive the prohibition under subsections 7a7 and 7b7 on a case-by-case basis-- 7i7 with the approval of the ,director of the ,office of ,management and ,budget1 in coordination with the ,secretary of ,defense2 and 7ii7 if such head submits a notification and justification to the appropriate congressional committees not later than #cj days after granting such waiver4 7,b7 ,duration 7i7 ,in general ,except as provided in clause 7ii71 a waiver granted under subparagraph 7,a7 shall last for a period of not more than #cfe days4 7ii7 ,extension ,the head of the applicable executive agency1 with the approval of the ,director of the ,office of ,management and ,budget1 and in coordination with the ,secretary of ,defense1 may extend a waiver granted under subparagraph 7,a7 one time1 for a period up to #ahj days after the date on which the waiver would otherwise expire1 if such an extension is in the national security interests of the ,united ,states and if such head submits a notification and justification to the appropriate congressional committees not later than #aj days after granting such waiver extension4 7#b7 ,overseas health care services ,the head of an executive agency may waive the prohibitions under subsections 7a7 and 7b7 with respect to a contract1 subcontract1 or transaction for the acquisition or provision of health care services overseas on a case-by-case basis-- 7,a7 if the head of such executive agency determines that the waiver is-- 7i7 necessary to support the mission or activities of the employees of such executive agency described in subsection 7e77#b77;,a72 and 7ii7 in the interest of the ,united ,states2 7,b7 with the approval of the ,director of the ,office of ,management and ,budget1 in consultation with the ,secretary of ,defense2 and 7,c7 if such head submits a notification and justification to the appropriate congressional committees not later than #cj days after granting such waiver4 7e7 ,exceptions ,the prohibitions under subsections 7a7 and 7b7 shall not apply to-- 7#a7 any activity subject to the reporting requirements under title ,v of the ,national ,security ,act of #aidg 7#ej ,u4,s4,c4 #cjia et seq47 or any authorized intelligence activities of the ,united ,states2 7#b7 the acquisition or provision of health care services overseas for-- 7,a7 employees of the ,united ,states1 including members of the uniformed services 7as defined in section #aja7;a7 of title #aj1 ,united ,states ,code71 whose official duty stations are located overseas or are on permissive temporary duty travel overseas2 or 7,b7 employees of contractors or subcontractors of the ,united ,states-- 7i7 who are performing under a contract that directly supports the missions or activities of individuals described in subparagraph 7,a72 and 7ii7 whose primary duty stations are located overseas or are on permissive temporary duty travel overseas2 or 7#c7 the acquisition1 use1 or distribution of human multiomic data1 lawfully compiled1 that is commercially or publicly available4 7f7 ,evaluation of certain biotechnology entities 7#a7 ,entity consideration ,not later than #cfe days after the date of the enactment of this ,act1 the ,director of the ,office of ,management and ,budget shall publish a list of the entities that constitute biotechnology companies of concern based on a list of suggested entities that shall be provided by the ,secretary of ,defense in coordination with the ,attorney ,general1 the ,secretary of ,health and ,human ,services1 the ,secretary of ,commerce1 the ,director of ,national ,intelligence1 the ,secretary of ,homeland ,security1 the ,secretary of ,state1 and the ,national ,cyber ,director4 7#b7 ,biotechnology companies of concern defined ,the term biotechnology company of concern means-- 7,a7 ,,bgi1 ,,mgi1 ,complete ,genomics1 ,wu,xi ,app,tec1 and ,wu,xi ,biologics2 7,b7 any entity that is determined by the process established in paragraph 7#a7 to meet the following criteria-- 7i7 is subject to the administrative governance structure1 direction1 control1 or operates on behalf of the government of a foreign adversary2 7ii7 is to any extent involved in the manufacturing1 distribution1 provision1 or procurement of a biotechnology equipment or service2 and 7iii7 poses a risk to the national security of the ,united ,states based on-- 7,i7 engaging in joint research with1 being supported by1 or being affiliated with a foreign adversary's military1 internal security forces1 or intelligence agencies2 7,,ii7 providing multiomic data obtained via biotechnology equipment or services to the government of a foreign adversary2 or 7,,iii7 obtaining human multiomic data via the biotechnology equipment or services without express and informed consent2 and 7,c7 any subsidiary1 parent1 affiliate1 or successor of entities listed in subparagraphs 7,a7 and 7,b71 provided they meet the criteria in subparagraph 7,b77i74 7#c7 ,guidance ,not later than #abj days after the date of the enactment of this ,act for the biotechnology companies of concern named in paragraph 7#b77;,a71 and not later than #ahj days after the development of the list pursuant to paragraph 7#a7 and any update to the list pursuant to paragraph 7#d71 the ,director of the ,office of ,management and ,budget1 in coordination with the ,secretary of ,defense1 the ,attorney ,general1 the ,secretary of ,health and ,human ,services1 the ,secretary of ,commerce1 the ,director of ,national ,intelligence1 the ,secretary of ,homeland ,security1 the ,secretary of ,state1 and the ,national ,cyber ,director1 shall establish guidance as necessary to implement the requirements of this section4 7#d7 ,updates ,the ,director of the ,office of ,management and ,budget1 in coordination with or based on a recommendation provided by the ,secretary of ,defense1 the ,attorney ,general1 the ,secretary of ,health and ,human ,services1 the ,secretary of ,commerce1 the ,director of ,national ,intelligence1 the ,secretary of ,homeland ,security1 the ,secretary of ,state1 and the ,national ,cyber ,director1 shall periodically1 though not less than annually1 review and1 as appropriate1 modify the list of biotechnology companies of concern1 and notify the appropriate congressional committees of any such modifications4 7#e7 ,notice of a designation and review 7,a7 ,in general ,a notice of a designation as a biotechnology company of concern under paragraph 7#b77;,b7 shall be issued to any biotechnology company of concern named in the designation-- 7i7 advising that a designation has been made2 7ii7 identifying the criteria relied upon under such subparagraph and1 to the extent consistent with national security and law enforcement interests1 the information that formed the basis for the designation2 7iii7 advising that1 within #ij days after receipt of notice1 the biotechnology company of concern may submit information and argument in opposition to the designation2 7iv7 describing the procedures governing the review and possible issuance of a designation pursuant to paragraph 7#a72 and 7v7 where practicable1 identifying mitigation steps that could be taken by the biotechnology company of concern that may result in the rescission of the designation4 7,b7 ,congressional notification requirements 7i7 ,notice of designation ,the ,director of the ,office of ,management and ,budget shall submit the notice required under subparagraph 7,a7 to the ,committee on ,homeland ,security and ,governmental ,affairs of the ,senate and the ,committee on ,oversight and ,accountability of the ,house of ,representatives4 7ii7 ,information and argument in opposition to designations ,not later than #g days after receiving any information and argument in opposition to a designation pursuant to subparagraph 7,a77iii71 the ,director of the ,office of ,management and ,budget shall submit such information to the ,committee on ,homeland ,security and ,governmental ,affairs of the ,senate and the ,committee on ,oversight and ,accountability of the ,house of ,representatives4 7,c7 ,exceptions ,the provisions under subparagraphs 7,a7 and 7,b7 shall not apply to an entity listed under paragraph 7#b77;,a74 7#f7 ,no immediate public release ,any designation made under paragraph 7#a7 or paragraph 7#d7 shall not be made publicly available until the ,director of the ,office of ,management and ,budget1 in coordination with appropriate agencies1 reviews all information submitted under paragraph 7#e77;,a77iii7 and issues a final determination that a company shall remain listed as a biotechnology company of concern4 7g7 ,evaluation of national security risks posed by foreign adversary acquisition of american multiomic data 7#a7 ,assessment ,not later than #bgj days after the enactment of this ,act1 the ,director of ,national ,intelligence1 in consultation with the ,secretary of ,defense1 the ,attorney ,general of the ,united ,states1 the ,secretary of ,health and ,human ,services1 the ,secretary of ,commerce1 the ,secretary of ,homeland ,security1 the ,secretary of ,state1 and the ,national ,cyber ,director1 shall complete an assessment of risks to national security posed by human multiomic data from ,united ,states citizens that is collected or stored by a foreign adversary from the provision of biotechnology equipment or services4 7#b7 ,report requirement ,not later than #cj days after the completion of the assessment developed under paragraph 7#a71 the ,director of ,national ,intelligence shall submit a report with such assessment to the appropriate congressional committees4 7#c7 ,form ,the report required under paragraph 7#b7 shall be in unclassified form accompanied by a classified annex4 7h7 ,regulations ,not later than one year after the date of establishment of guidance required under subsection 7f77#c71 and as necessary for subsequent updates1 the ,federal ,acquisition ,regulatory ,council shall revise the ,federal ,acquisition ,regulation as necessary to implement the requirements of this section4 7i7 ,reporting on intelligence on nefarious activities of biotechnology companies with human multiomic data ,not later than #ahj days after the date of the enactment of this ,act1 and annually thereafter1 the ,director of ,national ,intelligence1 in consultation with the heads of executive agencies1 shall submit to the appropriate congressional committees a report on any intelligence in possession of such agencies related to nefarious activities conducted by biotechnology companies with human multiomic data4 ,the report shall include information pertaining to potential threats to national security or public safety from the selling1 reselling1 licensing1 trading1 transferring1 sharing1 or otherwise providing or making available to any foreign country of any forms of multiomic data of a ,united ,states citizen4 7j7 ,no additional funds ,no additional funds are authorized to be appropriated for the purpose of carrying out this section4 7k7 ,definitions ,in this section3 7#a7 ,appropriate congressional committees ,the term appropriate congressional committees means-- 7,a7 the ,committee on ,armed ,services1 the ,select ,committee on ,intelligence1 and the ,committee on ,homeland ,security and ,governmental ,affairs of the ,senate2 and 7,b7 the ,committee on ,armed ,services1 the ,permanent ,select ,committee on ,intelligence1 the ,committee on ,foreign ,affairs1 the ,committee on ,oversight and ,accountability1 the ,committee on ,energy and ,commerce1 and the ,select ,committee on ,strategic ,competition between the ,united ,states and the ,chinese ,communist ,party of the ,house of ,representatives4 7#b7 ,biotechnology equipment or service ,the term biotechnology equipment or service means-- 7,a7 equipment1 including genetic sequencers1 combined mass spectrometry technologies1 polymerase chain reaction machines1 or any other instrument1 apparatus1 machine1 or device1 including components and accessories thereof1 that is designed for use in the research1 development1 production1 or analysis of biological materials as well as any software1 firmware1 or other digital components that are specifically designed for use in1 and necessary for the operation of1 such equipment2 7,b7 any service for the research1 development1 production1 analysis1 detection1 or provision of information1 including data storage and transmission related to biological materials1 including-- 7i7 advising1 consulting1 or support services with respect to the use or implementation of a instrument1 apparatus1 machine1 or device described in subparagraph 7,a72 and 7ii7 disease detection1 genealogical information1 and related services2 and 7,c7 any other service1 instrument1 apparatus1 machine1 component1 accessory1 device1 software1 or firmware that is designed for use in the research1 development1 production1 or analysis of biological materials that the ,director of the ,office of ,management and ,budget1 in consultation with the heads of ,executive agencies1 as determined appropriate by the ,director of the ,office of ,management and ,budget1 determines appropriate in the interest of national security4 7#c7 ,contract ,except as the term is used under subsection 7b77#b7 and subsection 7c77#c71 the term contract means any contract subject to the ,federal ,acquisition ,regulation issued under section #acjc7;a77#a7 of title #da1 ,united ,states ,code4 7#d7 ,control ,the term control has the meaning given to that term in section #hjj4bjh of title #ca1 ,code of ,federal ,regulations1 or any successor regulations4 7#e7 ,executive agency ,the term executive agency has the meaning given the term ,executive agency in section #aje of title #e1 ,united ,states ,code4 7#f7 ,foreign adversary ,the term foreign adversary has the meaning given the term covered nation in section #dhgb7;d7 of title #aj1 ,united ,states ,code4 7#g7 ,multiomic ,the term multiomic means data types that include genomics1 epigenomics1 transcriptomics1 proteomics1 and metabolomics4 7#h7 ,overseas ,the term overseas means any area outside of the ,united ,states1 the ,commonwealth of ,puerto ,rico1 or a territory or possession of the ,united ,states4 ,passed the ,house of ,representatives ,september #i1 #bjbd4;,clerk4